摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[4-Chloro-3-(trifluoromethyl)phenyl]-1-methylpiperidin-4-ol | 51788-00-2

中文名称
——
中文别名
——
英文名称
4-[4-Chloro-3-(trifluoromethyl)phenyl]-1-methylpiperidin-4-ol
英文别名
——
4-[4-Chloro-3-(trifluoromethyl)phenyl]-1-methylpiperidin-4-ol化学式
CAS
51788-00-2
化学式
C13H15ClF3NO
mdl
——
分子量
293.71
InChiKey
DUORAHWIVDIGKT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    23.5
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • Methods of Inhibiting Metastasis from Cancer
    申请人:Salvino Joseph M.
    公开号:US20120141471A1
    公开(公告)日:2012-06-07
    The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.
    本发明涉及一种用于预防或治疗被诊断为癌症的患者中的转移的组合物。本发明还包括一种用于预防或治疗被诊断为癌症的患者中的转移的方法,其中该方法包括向需要该药物的患者投与至少一种药用制剂,该制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
  • Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same
    申请人:Drexel University College of Medicine Philadelphia Health & Education Corporation d/b/a
    公开号:US20130156761A1
    公开(公告)日:2013-06-20
    The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.
    本发明涉及一种对已被诊断患有癌症的受试者预防或治疗转移的有用组合物。本发明还涉及一种预防或治疗已被诊断患有癌症的受试者的转移的方法,其中该方法包括向需要该药物的受试者施用至少一种药物制剂,该药物制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
  • Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs
    申请人:Frank Robert
    公开号:US20090215758A1
    公开(公告)日:2009-08-27
    The invention relates to 2,5-disubstituted thiazol-4-one derivatives and to their use in the production of drugs, to methods for producing them and to drugs containing said compounds.
    本发明涉及2,5-二取代噻唑-4-酮衍生物及其在药物生产中的应用,涉及其生产方法和含有该化合物的药物。
  • Compounds useful for inhibiting metastasis from cancer and methods using same
    申请人:Drexel University
    公开号:US10414771B2
    公开(公告)日:2019-09-17
    The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.
    本发明包括可用于预防或治疗确诊癌症患者转移的组合物。本发明还包括预防或治疗被诊断患有癌症的受试者的转移的方法,其中该方法包括向需要该方法的受试者施用有效量的药物制剂,该药物制剂包含至少一种药学上可接受的载体和至少一种CX3CR1或fractalkine拮抗剂。
  • NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS
    申请人:Sprout Pharmaceuticals, Inc.
    公开号:EP1322622B1
    公开(公告)日:2012-10-31
查看更多